Skip Nav Destination
Issues
1 August 2017
-
Cover Image
Cover Image
![issue cover]()
The cover shows a section of a primary tumor at diagnosis from a patient with metastatic colon cancer who failed a bevacizumab-containing regimen as first-line treatment. Immunohistochemical staining shows HOXB9 expression in tumor cells. For details, see the article by Carbone and colleagues on page 4312 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Regulatory Science and Policy
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C. Anderson; Daniel Auclair; Gary J. Kelloff; Caroline C. Sigman; Hervé Avet-Loiseau; Ann T. Farrell; Nicole J. Gormley; Shaji K. Kumar; Ola Landgren; Nikhil C. Munshi; Michele Cavo; Faith E. Davies; Alessandra Di Bacco; Jennifer S. Dickey; Steven I. Gutman; Howard R. Higley; Mohamad A. Hussein; J. Milburn Jessup; Ilan R. Kirsch; Richard F. Little; Robert D. Loberg; Jens G. Lohr; Lata Mukundan; James L. Omel; Trevor J. Pugh; Gregory H. Reaman; Michael D. Robbins; A. Kate Sasser; Nancy Valente; Elena Zamagni
Statistics in CCR
Molecular Pathways
Review
Cancer Therapy: Clinical
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Vivek Subbiah; Christian Meyer; Ralph Zinner; Funda Meric-Bernstam; Marianna L. Zahurak; Ashley O'Connor; Jason Roszik; Kenna Shaw; Joseph A. Ludwig; Razelle Kurzrock; Nilofer A. Azad
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović; Ingrid A. Mayer; Erica L. Mayer; Vandana G. Abramson; Aditya Bardia; Melinda E. Sanders; M. Gabriela Kuba; Monica V. Estrada; J. Scott Beeler; Timothy M. Shaver; Kimberly C. Johnson; Violeta Sanchez; Jennifer M. Rosenbluth; Patrick M. Dillon; Andres Forero-Torres; Jenny C. Chang; Ingrid M. Meszoely; Ana M. Grau; Brian D. Lehmann; Yu Shyr; Quanhu Sheng; Sheau-Chiann Chen; Carlos L. Arteaga; Jennifer A. Pietenpol
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Lee S. Schwartzberg; Denise A. Yardley; Anthony D. Elias; Manish Patel; Patricia LoRusso; Howard A. Burris; Ayca Gucalp; Amy C. Peterson; Martha E. Blaney; Joyce L. Steinberg; Jacqueline A. Gibbons; Tiffany A. Traina
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Cynthia X. Ma; Feng Gao; Jingqin Luo; Donald W. Northfelt; Matthew Goetz; Andres Forero; Jeremy Hoog; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Karen S. Anderson; Julie Margenthaler; Rebecca Aft; Timothy Hobday; Timothy Moynihan; William Gillanders; Amy Cyr; Timothy J. Eberlein; Tina Hieken; Helen Krontiras; Zhanfang Guo; Michelle V. Lee; Nicholas C. Spies; Zachary L. Skidmore; Obi L. Griffith; Malachi Griffith; Shana Thomas; Caroline Bumb; Kiran Vij; Cynthia Huang Bartlett; Maria Koehler; Hussam Al-Kateb; Souzan Sanati; Matthew J. Ellis
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo; Paul H. Frankel; Banu K. Arun; Cynthia X. Ma; Agustin A. Garcia; Tessa Cigler; Leah V. Cream; Harold A. Harvey; Joseph A. Sparano; Rita Nanda; Helen K. Chew; Timothy J. Moynihan; Linda T. Vahdat; Matthew P. Goetz; Jan H. Beumer; Arti Hurria; Joanne Mortimer; Richard Piekarz; Sharon Sand; Josef Herzog; Lily R. Van Tongeren; Katherine V. Ferry-Galow; Alice P. Chen; Christopher Ruel; Edward M. Newman; David R. Gandara; Jeffrey N. Weitzel
Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes
Chen Wang; Sebastian M. Armasu; Kimberly R. Kalli; Matthew J. Maurer; Ethan P. Heinzen; Gary L. Keeney; William A. Cliby; Ann L. Oberg; Scott H. Kaufmann; Ellen L. Goode
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux; Zhongwu Lai; Brian A. Dougherty; Sarah Runswick; Darren R. Hodgson; Kirsten M. Timms; Jerry S. Lanchbury; Stan Kaye; Charlie Gourley; David Bowtell; Elise C. Kohn; Claire Scott; Ursula Matulonis; Tony Panzarella; Katherine Karakasis; Julia V. Burnier; C. Blake Gilks; Mark J. O'Connor; Jane D. Robertson; Jonathan Ledermann; J. Carl Barrett; Tony W. Ho; Amit M. Oza
Author Choice
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit; Geoffrey I. Shapiro; Howard A. Burris; Amit M. Oza; Patricia LoRusso; Manish R. Patel; Susan M. Domchek; Judith Balmaña; Yvette Drew; Lee-may Chen; Tamar Safra; Ana Montes; Heidi Giordano; Lara Maloney; Sandra Goble; Jeff Isaacson; Jim Xiao; Jen Borrow; Lindsey Rolfe; Ronnie Shapira-Frommer
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra; Mieke W.H. Roeven; Jan Spanholtz; Basav N. Hangalapura; Marleen Tordoir; Frans Maas; Marij Leenders; Fenna Bohme; Nina Kok; Carel Trilsbeek; Jos Paardekooper; Anniek B. van der Waart; Peter E. Westerweel; Tjeerd J.F. Snijders; Jan Cornelissen; Gerard Bos; Hans F.M. Pruijt; Aniek O. de Graaf; Bert A. van der Reijden; Joop H. Jansen; Arnold van der Meer; Gerwin Huls; Jeannette Cany; Frank Preijers; Nicole M.A. Blijlevens; Nicolaas M. Schaap
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D. Soumerai; Andrew D. Zelenetz; Craig H. Moskowitz; M. Lia Palomba; Paul A. Hamlin, Jr; Ariela Noy; David J. Straus; Alison J. Moskowitz; Anas Younes; Matthew J. Matasar; Steven M. Horwitz; Carol S. Portlock; Jason A. Konner; Mrinal M. Gounder; David M. Hyman; Martin H. Voss; Matthew G. Fury; Devika Gajria; Richard D. Carvajal; Alan L. Ho; Jan H. Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F. Little; Christine Jarjies; Thu O. Dang; Fallon France; Nishant Mishra; John F. Gerecitano
Author Choice
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S. Czuczman; Marek Trněný; Andrew Davies; Simon Rule; Kim M. Linton; Nina Wagner-Johnston; Randy D. Gascoyne; Graham W. Slack; Pierre Brousset; David A. Eberhard; Francisco J. Hernandez-Ilizaliturri; Gilles Salles; Thomas E. Witzig; Pier Luigi Zinzani; George W. Wright; Louis M. Staudt; Yandan Yang; P. Mickey Williams; Chih-Jian Lih; Jacqueline Russo; Anjan Thakurta; Patrick Hagner; Pierre Fustier; Dale Song; Ian D. Lewis
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M. Parseghian; Nila U. Parikh; Ji Yuan Wu; Zhi-Qin Jiang; Laura Henderson; Feng Tian; Brice Pastor; Marc Ychou; Kanwal Raghav; Arvind Dasari; David R. Fogelman; Anastasia D. Katsiampoura; David G. Menter; Robert A. Wolff; Cathy Eng; Michael J. Overman; Alain R. Thierry; Gary E. Gallick; Scott Kopetz
Author Choice
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act
Kenneth L. Kehl; Cheryl P. Fullmer; Siqing Fu; Goldy C. George; Kenneth R. Hess; Filip Janku; Daniel D. Karp; Shumei Kato; Cynthia K. Kizer; Razelle Kurzrock; Aung Naing; Shubham Pant; Sarina A. Piha-Paul; Vivek Subbiah; Apostolia M. Tsimberidou; David S. Hong
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N. Stein; Joseph R. Bertino; Howard L. Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D. Aiken; Bruce G. Haffty; Robert S. DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S. El-Deiry; Joshua E. Allen; Martin Stogniew; Wolfgang Oster; Janice M. Mehnert
Personalized Medicine and Imaging
Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort
Anika Hüsing; Renée T. Fortner; Tilman Kühn; Kim Overvad; Anne Tjønneland; Anja Olsen; Marie-Christine Boutron-Ruault; Gianluca Severi; Agnes Fournier; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Philippos Orfanos; Giovanna Masala; Valeria Pala; Rosario Tumino; Francesca Fasanelli; Salvatore Panico; H. Bas Bueno de Mesquita; Petra H. Peeters; Carla H. van Gills; J. Ramón Quirós; Antonio Agudo; Maria-Jose Sánchez; Maria-Dolores Chirlaque; Aurelio Barricarte; Pilar Amiano; Kay-Tee Khaw; Ruth C. Travis; Laure Dossus; Kuanrong Li; Pietro Ferrari; Melissa A. Merritt; Ioanna Tzoulaki; Elio Riboli; Rudolf Kaaks
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee; Anthony F. Shields; Barry A. Siegel; Kathy D. Miller; Ian Krop; Cynthia X. Ma; Patricia M. LoRusso; Pamela N. Munster; Karen Campbell; Daniel F. Gaddy; Shannon C. Leonard; Elena Geretti; Stephanie J. Blocker; Dmitri B. Kirpotin; Victor Moyo; Thomas J. Wickham; Bart S. Hendriks
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831
Monica M. Reinholz; Beiyun Chen; Amylou C. Dueck; Kathleen Tenner; Karla Ballman; Darren Riehle; Robert B. Jenkins; Xochiquetzal J. Geiger; Ann E. McCullough; Edith A. Perez
Author Choice
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y. Huang; Yiping Shao; Laura Lam; Qing Yi; Y. Lynn Wang; Michael Wang
Author Choice
Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
M. Reza Abbasi; Fikret Rifatbegovic; Clemens Brunner; Georg Mann; Andrea Ziegler; Ulrike Pötschger; Roman Crazzolara; Marek Ussowicz; Martin Benesch; Georg Ebetsberger-Dachs; Godfrey C.F. Chan; Neil Jones; Ruth Ladenstein; Inge M. Ambros; Peter F. Ambros
Author Choice
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Rafal Panek; Liam Welsh; Lauren C.J. Baker; Maria A. Schmidt; Kee H. Wong; Angela M. Riddell; Dow-Mu Koh; Alex Dunlop; Dualta Mcquaid; James A. d'Arcy; Shreerang A. Bhide; Kevin J. Harrington; Christopher M. Nutting; Georgina Hopkinson; Cheryl Richardson; Carol Box; Suzanne A. Eccles; Martin O. Leach; Simon P. Robinson; Kate L. Newbold
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer
A.J. van der Wekken; R. Pelgrim; N. 't Hart; N. Werner; M.F. Mastik; L. Hendriks; E.H.F.M. van der Heijden; M. Looijen-Salamon; A.J. de Langen; J. Staal-van den Brekel; S. Riemersma; B.E. van den Borne; E.J.M. Speel; A-M.C. Dingemans; T.J.N. Hiltermann; A. van den Berg; W. Timens; E. Schuuring; H.J.M. Groen
Author Choice
Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma
Bin Zhang; Jie Tian; Di Dong; Dongsheng Gu; Yuhao Dong; Lu Zhang; Zhouyang Lian; Jing Liu; Xiaoning Luo; Shufang Pei; Xiaokai Mo; Wenhui Huang; Fusheng Ouyang; Baoliang Guo; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Cancer Therapy: Preclinical
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger; Christopher R. Zito; Gabriela Turcu; Marina K. Baine; Hongyi Zhang; Adebowale Adeniran; Mario Sznol; David L. Rimm; Yuval Kluger; Lieping Chen; Justine V. Cohen; Lucia B. Jilaveanu
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Carmine Carbone; Geny Piro; Francesca Simionato; Francesca Ligorio; Chiara Cremolini; Fotios Loupakis; Greta Alì; Daniele Rossini; Valeria Merz; Raffaela Santoro; Camilla Zecchetto; Marco Zanotto; Federica Di Nicolantonio; Alberto Bardelli; Gabriella Fontanini; Giampaolo Tortora; Davide Melisi
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B. Hanker; Joan T. Garrett; Mónica Valeria Estrada; Preston D. Moore; Paula González Ericsson; James P. Koch; Emma Langley; Sharat Singh; Phillip S. Kim; Garrett M. Frampton; Eric Sanford; Philip Owens; Jennifer Becker; M. Reid Groseclose; Stephen Castellino; Heikki Joensuu; Jens Huober; Jan C. Brase; Samira Majjaj; Sylvain Brohée; David Venet; David Brown; José Baselga; Martine Piccart; Christos Sotiriou; Carlos L. Arteaga
Author Choice
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen; Katja M. Fagerlund; Jukka P. Rissanen; Yvonne M. Konkol; Jukka P. Morko; ZhiQi Peng; Esa J. Alhoniemi; Salla K. Laine; Eva Corey; Dominik Mumberg; Karl Ziegelbauer; Sanna-Maria Käkönen; Jussi M. Halleen; Robert L. Vessella; Arne Scholz
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Yasmine Assadipour; Nikolaos Zacharakis; Jessica S. Crystal; Todd D. Prickett; Jared J. Gartner; Robert P.T. Somerville; Hui Xu; Mary A. Black; Li Jia; Harshini Chinnasamy; Isaac Kriley; Lily Lu; John R. Wunderlich; Zhili Zheng; Yong-Chen Lu; Paul F. Robbins; Steven A. Rosenberg; Stephanie L. Goff; Steven A. Feldman
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
Sandra Rebouissou; Tiziana La Bella; Samia Rekik; Sandrine Imbeaud; Anna-Line Calatayud; Nataliya Rohr-Udilova; Yoann Martin; Gabrielle Couchy; Paulette Bioulac-Sage; Bettina Grasl-Kraupp; Leanne de Koning; Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Jessica Zucman-Rossi
Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Haibo Sun; De-Chen Lin; Qi Cao; Brendan Pang; David D. Gae; Victor Kwan Min Lee; Huey Jin Lim; Ngan Doan; Jonathan W. Said; Sigal Gery; Marilynn Chow; Anand Mayakonda; Charles Forscher; Jeffrey W. Tyner; H. Phillip Koeffler
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Dennis Shin-Shian Hsu; Wei-Lun Hwang; Chiou-Hwa Yuh; Chen-Hsi Chu; Yang-Hui Ho; Pon-Bo Chen; Han-Syuan Lin; Hua-Kuo Lin; Shih-Pei Wu; Chih-Yi Lin; Wen-Hao Hsu; Hsin-Yi Lan; Hsiao-Jung Wang; Shyh-Kuan Tai; Mien-Chie Hung; Muh-Hwa Yang
Biology of Human Tumors
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Charlotte K.Y. Ng; Francois-Clement Bidard; Salvatore Piscuoglio; Felipe C. Geyer; Raymond S. Lim; Ino de Bruijn; Ronglai Shen; Fresia Pareja; Samuel H. Berman; Lu Wang; Jean-Yves Pierga; Anne Vincent-Salomon; Agnes Viale; Larry Norton; Brigitte Sigal; Britta Weigelt; Paul Cottu; Jorge S. Reis-Filho
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Nicolas A. Giraldo; Etienne Becht; Yann Vano; Florent Petitprez; Laetitia Lacroix; Pierre Validire; Rafael Sanchez-Salas; Alexandre Ingels; Stephane Oudard; Audrey Moatti; Benedicte Buttard; Sarah Bourass; Claire Germain; Xavier Cathelineau; Wolf H. Fridman; Catherine Sautès-Fridman
Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Erik S. Knudsen; Paris Vail; Uthra Balaji; Hoai Ngo; Ihab W. Botros; Vladimir Makarov; Nadeem Riaz; Vinod Balachandran; Steven Leach; Debrah M. Thompson; Timothy A. Chan; Agnieszka K. Witkiewicz
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Bo Hwa Sohn; Jun-Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Sang Cheul Oh; Jae-Jun Shim; Keun-Wook Lee; Eui Hyun Kim; Sun Young Yim; Sang Ho Lee; Jae-Ho Cheong; Woojin Jeong; Jae Yong Cho; Joohee Kim; Jungsoo Chae; Jeeyun Lee; Won Ki Kang; Sung Kim; Sung Hoon Noh; Jaffer A. Ajani; Ju-Seog Lee
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Ombretta Melaiu; Marco Mina; Marco Chierici; Renata Boldrini; Giuseppe Jurman; Paolo Romania; Valerio D'Alicandro; Maria C. Benedetti; Aurora Castellano; Tao Liu; Cesare Furlanello; Franco Locatelli; Doriana Fruci
Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Johanne I. Weberpals; Bryan Lo; Marc M. Duciaume; Johanna N. Spaans; Aisling A. Clancy; Jim Dimitroulakos; Glenwood D. Goss; Harman S. Sekhon
Retraction
Advertisement
